Methods: A retrospective chart review was conducted. A query of the electronic medical record was used to identify patients with a diagnosis of UTI who were prescribed a fluoroquinolone. Data collected included baseline demographics, antibiotic allergies, culture data, days of therapy, and reported adverse events. A letter to healthcare providers focusing on fluoroquinolone avoidance in UTI treatment was distributed, and a new UTI treatment pathway was published in a newsletter sent to healthcare providers and posted throughout the institution. The primary endpoint of the study was the appropriateness of fluoroquinolone use for treatment of UTI before and after the intervention. Secondary endpoints included duration of therapy and percentage of patients prescribed a fluoroquinolone for UTI versus other antibiotics.
Results: A total of 212 patient charts were reviewed, 159 patients in the pre-intervention group and 53 in the post-intervention group. In the pre-intervention group, use was appropriate in 19% (30/159) of patients who received a fluoroquinolone versus 47.2% (25/53) in the post-intervention group (P <0.001). In the inpatient setting, appropriateness of use increased from 24.1% in the pre-intervention group to 57.1% in the post-intervention group (P = 0.007). In the outpatient setting, appropriateness of use increased from 16% to 40.6% (P = 0.005).
Conclusion: Implementation of a clinical pathway, along with provider education, demonstrated a statistically significant reduction in the inappropriate use of fluoroquinolones for the treatment of UTI in both the inpatient and outpatient setting.
B. Peters, None
T. Ikerd, None
See more of: Poster Abstract Session